NeuroLink Therapeutics is a biotechnology company based in Cambridge, operating in the neuroscience and therapeutic development sector. The company appears to focus on developing treatments or technologies related to neurological conditions, leveraging the intersection of neuroscience and therapeutic innovation.
With $45 million raised in Series A funding, NeuroLink Therapeutics has secured substantial capital to advance its research and development programs. Cambridge's position as a premier biotech hub, with proximity to leading academic institutions like Harvard and MIT, as well as major pharmaceutical companies, provides the company with access to world-class scientific talent and industry partnerships. The significant Series A investment suggests the company has demonstrated promising preclinical or clinical data in its therapeutic programs and is advancing toward potential commercialization.
| Date | Round | Amount | Lead Investor |
|---|---|---|---|
| Feb 2026 | Series A | $45M | a16z Bio Fund |
A Cambridge-based biotech company developing neurological therapeutics and treatments.
NeuroLink Therapeutics has raised $45M in total funding, with their most recent round being a Series A. The company operates in the Biotech sector.
NeuroLink Therapeutics operates in the Biotech sector. A Cambridge-based biotech company developing neurological therapeutics and treatments.
